By the ZIVOLABS Medical Team · Updated April 2026 · 9 min read

If you have PCOD and you have been told to "just lose weight" — you already know how unhelpful that advice is. The cruel reality of PCOD is that the condition itself makes weight loss harder than it is for people without it. And the weight gain makes the PCOD worse. It is a loop that diet and exercise alone rarely break.

GLP-1 medication like semaglutide is now being used by doctors specifically for this cycle — and the results are meaningful. Here is what the science says, what Indian doctors are seeing, and what you need to know before considering it.

Why PCOD causes weight gain that is so hard to lose

PCOD (Polycystic Ovarian Disease, also called PCOS) is fundamentally a hormonal and metabolic condition. Most people understand the symptoms — irregular periods, cysts on the ovaries, excess hair growth, acne — but fewer understand why weight is so central to the condition.

Here is what is actually happening:

Insulin resistance is at the root. Most women with PCOD have some degree of insulin resistance, meaning their cells do not respond normally to insulin. The body compensates by producing more insulin. High insulin levels directly stimulate the ovaries to produce more androgens (male hormones like testosterone). Those androgens drive many of the classic PCOD symptoms — and they also promote fat storage, particularly around the abdomen.

Your body is working against you. Because of this hormonal environment, your body is primed to store fat and resist burning it. The same calorie deficit that produces weight loss in a person without PCOD may produce little or no result in a woman with PCOD. This is not a willpower failure. It is biology.

Weight gain worsens insulin resistance. More body fat — especially abdominal fat — makes insulin resistance worse, which raises insulin levels further, which drives more androgen production, which worsens the PCOD. This is the loop that many women are trapped in for years.

How GLP-1 medication addresses the PCOD cycle

Semaglutide targets this cycle in two important ways.

It directly reduces insulin resistance. GLP-1 medications were originally developed for Type 2 diabetes precisely because they improve the body's response to insulin. In PCOD, where insulin resistance is a root driver, this is directly relevant — not incidental.

It produces meaningful weight loss. Clinical trials show average weight loss of 10–15% of body weight on semaglutide. In PCOD, even a 5–10% reduction in body weight has been shown to improve menstrual regularity, reduce androgen levels, improve ovulation, and in some cases restore fertility. The weight loss from semaglutide is typically far greater than that threshold.

The result is that GLP-1 medication addresses PCOD from two directions simultaneously — directly improving insulin sensitivity, and indirectly improving the hormonal picture through weight reduction.

What the research shows

The clinical evidence specifically for GLP-1 medications in PCOD is still building, but what exists is promising — and the underlying mechanism is well understood.

A 2023 study published in the Journal of Clinical Endocrinology and Metabolism found that women with PCOD and obesity who were treated with semaglutide showed significant reductions in body weight, fasting insulin, testosterone levels, and improvements in menstrual cycle regularity compared to placebo — all within 6 months.

Separately, the landmark STEP trials (which led to semaglutide's global approvals) included a significant proportion of women with PCOD among participants. The metabolic improvements — reduced insulin resistance, lower inflammatory markers, better lipid profiles — were consistent across this subgroup.

Indian endocrinologists treating PCOD patients with semaglutide are reporting what the trials suggest: regular periods returning, reduced androgen symptoms, and weight loss that responds to the medication in a way it never did to diet and exercise alone.

What results can you realistically expect?

Every person with PCOD presents differently, and results vary. But based on clinical evidence, here is a realistic picture for a woman with PCOD on semaglutide for 6–12 months:

Weight loss: 8–15% of body weight on average. For a woman weighing 80 kg, that is 6–12 kg. For a woman weighing 95 kg, that is 8–14 kg. This is significantly more than most PCOD patients achieve through diet modification alone.

Menstrual regularity: Many women with PCOD report improvement in cycle regularity within 3–6 months, particularly those who were previously irregular due to anovulation (failure to ovulate). This is linked directly to the reduction in insulin and androgen levels.

Androgen symptoms: Symptoms like excess facial hair (hirsutism) and acne tend to improve more slowly — over 6–12 months — as androgen levels gradually normalise. Semaglutide is not a quick fix for these symptoms, but it addresses their root cause in a way that topical treatments do not.

Fertility: For women with PCOD who are trying to conceive, weight loss of 5–10% has been associated with restored ovulation in clinical literature. Semaglutide is not currently approved as a fertility treatment, and women who become pregnant must stop the medication. But for women whose PCOD-related weight gain has been a barrier to conception, it is relevant.

Is semaglutide safe for women with PCOD?

Yes — with the important caveat that it must be prescribed and monitored by a doctor who knows your full history.

Semaglutide is not suitable during pregnancy or while trying to conceive. Women who are actively trying to get pregnant should discuss this clearly with their doctor before starting. Contraception is typically recommended during treatment.

Women with PCOD who are also on metformin (a common first-line treatment for insulin resistance in PCOD) can often take semaglutide alongside it — the two work through different mechanisms and are commonly used together. Your doctor will review your current medications.

The common side effects — nausea, mild digestive discomfort in the first few weeks — are the same as for any semaglutide patient. They are temporary and manageable.

GLP-1 vs metformin for PCOD — how do they compare?

Metformin is currently the most commonly prescribed medication for the metabolic component of PCOD in India. It reduces insulin resistance and can help with weight and cycle regulation. So how does semaglutide compare?

Metformin remains a reasonable first-line option, particularly for newly diagnosed patients or those with milder symptoms. But for women who have been on metformin for years and are still struggling with weight and symptoms, semaglutide represents a significantly more powerful metabolic intervention.

Many Indian doctors are now combining both — using metformin to manage insulin resistance at a baseline level and adding semaglutide for patients who need more substantial metabolic support and weight loss.

What PCOD patients in India are asking their doctors

"My periods have been irregular for 10 years. Can semaglutide fix this?" There is no guarantee — but clinical evidence shows that meaningful weight loss (which semaglutide consistently produces) and improved insulin sensitivity directly improve menstrual regularity in PCOD. Many patients report cycle improvement within 3–6 months.

"I have been told my PCOD will improve if I lose weight — but I cannot lose weight. Is this medication for me?" This is the exact patient profile that GLP-1 medication was designed for. The inability to lose weight despite effort is not a character flaw — it is a biological consequence of the insulin resistance and hormonal environment that PCOD creates. Semaglutide addresses that environment directly.

"I am trying to get pregnant. Should I take this?" No — not while actively trying to conceive. Semaglutide is not safe during pregnancy and must be stopped before attempting conception. However, for women who are not yet ready to try and want to improve their metabolic health first, it can be a meaningful part of that preparation.

"I already take metformin and birth control for PCOD. Can I add this?" Your doctor will review the full picture. In many cases, semaglutide can be added alongside existing medication. The ZIVOLABS health assessment will flag any interactions and your consulting doctor will advise you directly.

"Will I have to take this forever?" Not necessarily. Some patients with PCOD reach a point where sustained weight loss has improved their insulin resistance enough that their hormonal picture normalises. Others choose to continue long-term to maintain results. This is a conversation to have with your doctor after 6–12 months of treatment, once your body's response is clear.

Who with PCOD qualifies for GLP-1 medication?

You are likely a candidate for semaglutide if you have PCOD and meet any of the following:

• BMI of 27.5 or above

• Insulin resistance or elevated fasting insulin on blood tests

• Difficulty losing weight despite dietary effort

• Associated conditions such as pre-diabetes or metabolic syndrome

• Irregular periods linked to anovulation and weight

A ZIVOLABS doctor will review your health assessment, current medications, and relevant bloodwork before making a recommendation.

Ready to break the cycle?

PCOD-related weight gain is not a lifestyle failure. It is a medical problem that deserves a medical solution. A ZIVOLABS doctor can assess your profile and let you know whether GLP-1 medication is appropriate for your specific situation — in a single online consultation, without a clinic visit.

[Start your free health assessment →]

This article is for informational purposes only and does not constitute medical advice. Semaglutide is a prescription medication and is not suitable during pregnancy or while trying to conceive. Always consult a qualified doctor before starting any new treatment. Individual results may vary.